Miragen Therapeutics (NASDAQ:MGEN) and Celcuity (NASDAQ:CELC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.
Profitability
This table compares Miragen Therapeutics and Celcuity's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Miragen Therapeutics | -1,393.50% | -141.66% | -88.74% |
| Celcuity | N/A | -52.57% | -49.69% |
Insider and Institutional Ownership
18.6% of Celcuity shares are owned by institutional investors. 1.1% of Miragen Therapeutics shares are owned by company insiders. Comparatively, 43.5% of Celcuity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Miragen Therapeutics and Celcuity's gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Miragen Therapeutics | $4.46 million | 14.41 | $-41,870,000.00 | ($20.09) | -0.82 |
| Celcuity | N/A | N/A | $-7,360,000.00 | ($0.72) | -19.72 |
Celcuity has lower revenue, but higher earnings than Miragen Therapeutics. Celcuity is trading at a lower price-to-earnings ratio than Miragen Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and price targets for Miragen Therapeutics and Celcuity, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Miragen Therapeutics | 0 | 1 | 5 | 0 | 2.83 |
| Celcuity | 0 | 0 | 2 | 0 | 3.00 |
Miragen Therapeutics currently has a consensus target price of $16.3333, suggesting a potential downside of 0.65%. Celcuity has a consensus target price of $21.50, suggesting a potential upside of 51.41%. Given Celcuity's stronger consensus rating and higher possible upside, analysts plainly believe Celcuity is more favorable than Miragen Therapeutics.
Risk and Volatility
Miragen Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, Celcuity has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500.
Summary
Celcuity beats Miragen Therapeutics on 9 of the 13 factors compared between the two stocks.
